作者: Anandi N. Sheth , Charlotte P. Rolle , Monica Gandhi
DOI: 10.1016/S2055-6640(20)30458-1
关键词:
摘要: Women and girls comprise nearly half of HIV-infected individuals globally 20% new infections in the United States, indicating an urgent need to optimise HIV prevention options this population. pre-exposure prophylaxis (PrEP) - where antiretrovirals are administered HIV-non-infected at risk acquisition is a promising, female-controlled strategy but has so far been underutilised women. Clinical trial data demonstrate efficacy daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for reduction among women when used consistently. Limited perception suboptimal PrEP awareness healthcare personnel challenges with delivery Future research into development drugs systems, integrating reproductive services, provide opportunities